We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VIEW
2476
DELISTED
View, Inc. Class A Common Stock
VIEW
| $584K | ﹤0.01% |
1,795
+131
| +8% | +$46K |
|
|
EPZM
2477
DELISTED
Epizyme, Inc
EPZM
| $583K | ﹤0.01% |
113,839
-18,691
| -14% | -$114K |
|
2478
Nordic American Tanker
NAT
$1.37B
| $582K | ﹤0.01% |
227,396
+1,054
| +0.5% | +$2.65K |
|
2479
Recursion Pharmaceuticals
RXRX
$1.73B
| $582K | ﹤0.01% |
25,284
+4,466
| +21% | +$127K |
|
2480
OneSpaWorld
OSW
$2.66B
| $578K | ﹤0.01% |
57,947
+2,128
| +4% | +$21K |
|
2481
Veru
VERU
$37.4M
| $575K | ﹤0.01% |
6,735
+270
| +4% | +$21.4K |
|
|
HCCI
2482
DELISTED
Heritage-Crystal Clean, Inc.
HCCI
| $574K | ﹤0.01% |
19,819
+315
| +2% | +$9.01K |
|
|
GNOG
2483
DELISTED
Golden Nugget Online Gaming, Inc. Class A Common Stock
GNOG
| $573K | ﹤0.01% |
32,999
+6,812
| +26% | +$114K |
|
|
FPI
2484
Farmland Partners
FPI
$432M
| $571K | ﹤0.01% |
47,648
+1,892
| +4% | +$23.3K |
|
2485
CNB Financial Corp
CCNE
$1.03B
| $569K | ﹤0.01% |
23,364
+750
| +3% | +$18K |
|
2486
Seres Therapeutics
MCRB
$48.4M
| $568K | ﹤0.01% |
4,078
+136
| +3% | +$26.6K |
|
2487
American Outdoor Brands
AOUT
$157M
| $565K | ﹤0.01% |
22,995
+482
| +2% | +$13.5K |
|
2488
FRP Holdings
FRPH
$421M
| $563K | ﹤0.01% |
20,146
+370
| +2% | +$10.6K |
|
|
GRTS
2489
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $563K | ﹤0.01% |
52,129
+1,900
| +4% | +$17.3K |
|
|
QUOT
2490
DELISTED
Quotient Technology Inc
QUOT
| $563K | ﹤0.01% |
96,711
+3,785
| +4% | +$31.7K |
|
|
ALBO
2491
DELISTED
Albireo Pharma Inc
ALBO
| $563K | ﹤0.01% |
18,060
+601
| +3% | +$18.6K |
|
2492
PAVmed
PAVM
$33.9M
| $562K | ﹤0.01% |
146
+6
| +4% | +$18.9K |
|
2493
DoubleVerify
DV
$2.03B
| $561K | ﹤0.01% |
16,419
+3,925
| +31% | +$139K |
|
2494
Keros Therapeutics
KROS
$221M
| $561K | ﹤0.01% |
14,185
+680
| +5% | +$24.2K |
|
2495
Clearfield
CLFD
$374M
| $560K | ﹤0.01% |
12,688
+520
| +4% | +$21.9K |
|
2496
Karyopharm Therapeutics
KPTI
$48M
| $560K | ﹤0.01% |
6,413
-1,966
| -23% | -$204K |
|
2497
Phathom Pharmaceuticals
PHAT
$692M
| $560K | ﹤0.01% |
17,454
+1,016
| +6% | +$33.8K |
|
2498
Miller Industries
MLR
$619M
| $559K | ﹤0.01% |
16,430
+525
| +3% | +$19.4K |
|
2499
Nkarta
NKTX
$172M
| $558K | ﹤0.01% |
20,077
+675
| +3% | +$21.4K |
|
2500
W&T Offshore
WTI
$518M
| $557K | ﹤0.01% |
149,613
+2,898
| +2% | +$10.4K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.